使用CTLA-4疗法洗牌：重排的TCRB基因深度测序证明癌症患者的T细胞受体库重塑。
Shuffling the deck with CTLA-4 therapy: Deep sequencing of rearranged TCRB genes demonstrates T cell repertoire remodeling in cancer patients.
作者信息
Cha Edward, Fong Lawrence
机构信息
University of California, San Francisco, San Francisco, CA.
出版信息
Oncoimmunology. 2018 Mar 13;7(4):e956016. doi: 10.4161/21624011.2014.956016. eCollection 2018.
Abstract
CTLA-4 inhibition produces durable T cell-driven antitumor responses, but understanding which patients achieve a long-term benefit remains unclear. Deep sequencing of rearranged T cell receptor β (TCRβ) genes can monitor the effects of CTLA-4 inhibition and potentially identify patients with long-term survival.
摘要
细胞毒性T淋巴细胞相关抗原4（CTLA-4）抑制可产生持久的T细胞驱动的抗肿瘤反应，但哪些患者能获得长期益处仍不清楚。重排的T细胞受体β（TCRβ）基因的深度测序可监测CTLA-4抑制的效果，并有可能识别出长期存活的患者。
相似文献
1
Shuffling the deck with CTLA-4 therapy: Deep sequencing of rearranged TCRB genes demonstrates T cell repertoire remodeling in cancer patients.
Oncoimmunology. 2018 Mar 13;7(4):e956016. doi: 10.4161/21624011.2014.956016. eCollection 2018.
2
TCR Convergence in Individuals Treated With Immune Checkpoint Inhibition for Cancer.
Front Immunol. 2020 Jan 9;10:2985. doi: 10.3389/fimmu.2019.02985. eCollection 2019.
3
Radiotherapy and CTLA-4 Blockade Shape the TCR Repertoire of Tumor-Infiltrating T Cells.
Cancer Immunol Res. 2018 Feb;6(2):139-150. doi: 10.1158/2326-6066.CIR-17-0134. Epub 2017 Nov 27.
4
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3 Regulatory T Cells (Tregs) in Human Cancers.
Clin Cancer Res. 2019 Feb 15;25(4):1233-1238. doi: 10.1158/1078-0432.CCR-18-0762. Epub 2018 Jul 27.
5
Remarkably similar CTLA-4 binding properties of therapeutic ipilimumab and tremelimumab antibodies.
Oncotarget. 2017 May 19;8(40):67129-67139. doi: 10.18632/oncotarget.18004. eCollection 2017 Sep 15.
6
CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.
Clin Cancer Res. 2013 Oct 1;19(19):5300-9. doi: 10.1158/1078-0432.CCR-13-0143.
7
Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire.
Cancer Res. 2017 Mar 15;77(6):1322-1330. doi: 10.1158/0008-5472.CAN-16-2324. Epub 2016 Dec 28.
8
Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy.
Cancer Immunol Res. 2016 Oct;4(10):835-844. doi: 10.1158/2326-6066.CIR-16-0013. Epub 2016 Sep 1.
9
Therapeutic use of anti-CTLA-4 antibodies.
Int Immunol. 2015 Jan;27(1):3-10. doi: 10.1093/intimm/dxu076. Epub 2014 Jul 18.
10
CTLA-4 blockade with monoclonal antibodies in patients with metastatic cancer: surgical issues.
Ann Surg Oncol. 2008 Nov;15(11):3014-21. doi: 10.1245/s10434-008-0104-y. Epub 2008 Aug 21.
引用本文的文献
1
NHS-IL12, a Tumor-Targeting Immunocytokine.
Immunotargets Ther. 2021 May 27;10:155-169. doi: 10.2147/ITT.S306150. eCollection 2021.
2
T cell receptor repertoire characteristics both before and following immunotherapy correlate with clinical response in mesothelioma.
J Immunother Cancer. 2020 Mar;8(1). doi: 10.1136/jitc-2019-000251.
3
First-in-Human Phase I Trial of a Tumor-Targeted Cytokine (NHS-IL12) in Subjects with Metastatic Solid Tumors.
Clin Cancer Res. 2019 Jan 1;25(1):99-109. doi: 10.1158/1078-0432.CCR-18-1512. Epub 2018 Aug 21.
本文引用的文献
1
Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions.
Clin Cancer Res. 2014 Jul 1;20(13):3401-10. doi: 10.1158/1078-0432.CCR-14-0433.
2
Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients.
Sci Transl Med. 2014 May 28;6(238):238ra70. doi: 10.1126/scitranslmed.3008211.
3
Combining next-generation sequencing and immune assays: a novel method for identification of antigen-specific T cells.
PLoS One. 2013 Sep 19;8(9):e74231. doi: 10.1371/journal.pone.0074231. eCollection 2013.
4
Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma.
J Clin Oncol. 2013 Nov 10;31(32):e439-42. doi: 10.1200/JCO.2012.47.7521. Epub 2013 Sep 16.
5
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma.
Ann N Y Acad Sci. 2013 Jul;1291(1):1-13. doi: 10.1111/nyas.12180. Epub 2013 Jun 17.
6
Unmasking the immune recognition of prostate cancer with CTLA4 blockade.
Nat Rev Cancer. 2012 Mar 1;12(4):289-97. doi: 10.1038/nrc3223.
7
Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival.
Cancer. 2010 Apr 1;116(7):1767-75. doi: 10.1002/cncr.24951.
8
CTLA4 blockade increases Th17 cells in patients with metastatic melanoma.
J Transl Med. 2009 May 20;7:35. doi: 10.1186/1479-5876-7-35.
9
Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF.
Cancer Res. 2009 Jan 15;69(2):609-15. doi: 10.1158/0008-5472.CAN-08-3529.
10
Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma.
J Transl Med. 2008 May 1;6:22. doi: 10.1186/1479-5876-6-22.
Zotero 插件